Presentations

08:00

Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection

Andrew B. Adams (US)

Bio Abstract

08:13

CCL22-engineered MSCs modulate immune crosstalk to shape an immunosuppressive microenvironment for graft protection

Yanan Li (CN)

Bio Abstract

08:23

Efficacy and safety of everolimus added to Tacrolimus/Mycophenolate/Prednisone in HLA-sensitized kidney transplant recipients: A randomized controled trial.

Elias David-Neto (BR)

Bio Abstract

08:30

🎗Targeted Elimination of ABO-Specific B Cells via Bispecific T-Cell-Engaging Antibody Conjugates for ABO-Incompatible Kidney Transplantation

Joon Young Jang (KR)

Bio Abstract

08:37

🎗CCR10 Defines a Potent Regulatory T Cell Subset Essential for Kidney Transplant Tolerance through Enhanced Foxp3 Lineage Stability

Siyue Chen (CN)

Bio Abstract

08:44

Comparative effectiveness of thymoglobulin versus basiliximab for induction immunosuppression in older kidney transplant recipients: A target trial emulation

Katharine Krupp (US)

Bio Abstract

08:49

Bioequivalence of generic immunosuppressants in kidney transplants

Anders Asberg (NO)

Bio Abstract